NAD+ × Pure Health Peptides — Lab Test, October 2025
BioRegen publishes a public verification portal. Any test attributed to this lab can be looked up and confirmed directly with the lab — so this result doesn't rest on our review alone. Click 'Verify' (top right), then enter COA Number + Validation Key from the COA
This certificate carries no lookup code.
Test results
This is a purity and identity analysis. Sterility, endotoxins, and heavy metals were not screened — a high purity figure says nothing about those.
About this test
Label 500 mg · Lab measured 669 mg
134% of label, basis not stated — shown as printed. Reconstituted with 2 mL, a 50-unit draw holds 167.3 mg using the measured mass, against 125 mg on the label — 34% more.
One vial from this lot was weighed by the laboratory, not yours. This page reports what the certificate says; it does not recommend a dose.
Independent HPLC purity analysis of NAD+ from purehealthpeptides.com, performed by BioRegen on October 22, 2025. Reported purity: 99.53%. Net content: 669 mg against 500 mg labeled (134% of label). Tested content exceeds the labeled amount by 34%. Batch TUY-101025. Sample source: shop-provided. Certificate of analysis attached.
Certificate of analysis
Other lots of NAD+ from purehealthpeptides.com
| Lot | Tested | Lab | Purity | vs label | Status |
|---|---|---|---|---|---|
| TUY-030926 | 12 Apr 2026 | Ethos Analytics | 99% | 107% | Lab has no portal |
| CHA-011926 | 11 Feb 2026 | Bioviridian | 99.8% | 101% | Unverified |
| RPL-011526 | 11 Feb 2026 | Bioviridian | 99.8% | 101% | Unverified |
| RPL-010826 | 18 Jan 2026 | Ethos Analytics | 99% | 106% | Lab has no portal |
| TUY-101025 | 22 Oct 2025 | BioRegen | 99.24% | 115% | Unverified |
| CHA-041525 | 9 May 2025 | BioRegen | 99.39% | 209% | Unverified |
Batches this shop has published a certificate for, newest first. A lot whose printed value cannot identify a batch is not listed.
Have you tested this peptide?
Submit your third-party lab test to help the community verify purity claims. Every report is reviewed before publication.
Community discussion